Previous 10 | Next 10 |
HST Global Inc (HSTC) is expected to report for quarter end 2023-09-30 Air China Ltd ADR - Level I (AIRYY) is expected to report for Q3 2023 GrafTech International Ltd. (EAF) is expected to report $-0.05 for Q3 2023 Cardinal Health Inc. (CAH) is expected to report $1.4 for Q1 2024 ...
Core Revenue of $66 million represents Growth of 17% Year-over-Year Additional Reimbursement from COVID-19 Test Sales yields Revenue of $19 million, for Total Revenue of $85 million Reiterates Full Year 2023 Core Revenue Guidance of $260 million Fulgent Genetics, Inc. (NASDAQ: F...
Fulgent Genetics Inc. (FLGT) is expected to report $-0.61 for Q3 2023
2023-11-02 11:29:27 ET More on Fulgent Genetics Fulgent Genetics: Navigating Post-COVID Growing Pains Seeking Alpha’s Quant Rating on Fulgent Genetics Historical earnings data for Fulgent Genetics Financial information for Fulgent Genetics For ...
Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established clinical diagnostic business and a therapeutic development business, today announced two upcoming poster presentations at the Society for Immunotherap...
Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established clinical diagnostic business and a therapeutic development business, today announced that it will release its third quarter 2023 financial results bef...
2023-09-21 17:06:24 ET Summary Fulgent Genetics saw robust Q2 revenue growth at $68M but struggled with a GAAP loss of $11.2M, suggesting strategic investments. The firm boasts significant liquidity ($846.8M), allowing for potential acquisitions or growth initiatives, yet operatio...
2023-08-04 10:33:05 ET Fulgent Genetics, Inc. (FLGT) Q2 2023 Earnings Conference Call August 04, 2023, 8:30 AM ET Company Participants Melanie Solomon - Investor Relations Ming Hsieh - Chief Executive Officer Brandon Perthuis - Chief Commercial Officer Paul K...
2023-08-04 07:12:10 ET Fulgent Genetics press release ( NASDAQ: FLGT ): Q2 Non-GAAP EPS of -$0.08 beats by $0.25 . Revenue of $67.85M (-45.9% Y/Y) beats by $5.37M . Adjusted EBITDA loss of $2.7 million. Generated cash flow from operations of $9.7 million. ...
Total Revenue of $68 million Record Core Revenue of $67 million, growth of 48% year-over-year Raises Full Year 2023 Core Revenue Guidance to $260 million and Narrows Expected Loss Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a t...
News, Short Squeeze, Breakout and More Instantly...
Fulgent Genetics Inc. Company Name:
FLGT Stock Symbol:
NASDAQ Market:
Fulgent Genetics Inc. Website:
Collaboration aims to accelerate the development of personalized therapies and transform patient care through the use of precision medicine Moffitt Cancer Center, a world-renowned cancer treatment and research center, and Fulgent Pharma, a subsidiary of Fulgent Genetics, Inc. (NASDAQ: F...
Commercial National Financial Corp. (CNAF) is expected to report for Q1 2024 First National Bank Alaska (FBAK) is expected to report for Q1 2024 Cyxtera Technologies Inc. (CYXTQ) is expected to report for quarter end 2024-03-31 Brookfield Renewable Corporation Class A Subordinate (BEP...